“Leaky” tumor blood vessels promote access of liposomes

Heat application further increases liposomal penetration

Heat-sensitive liposomes selectively release chemotherapeutic agent

LTSL technology is agnostic regarding the means of heating. Whether combined with radiofrequency thermal ablation (RFA) to expand the “treatment zone” for solid tumors, microwave ablation for superficial tumors, or high-intensity focused ultrasound for difficult to reach tumors, LTSL has shown its mechanism to be effective.
While ThermoDox®, liposomal encapsulation of doxorubicin, is our first investigational product developed through application of LTSL technology, the LTSL platform has shown its applicability to a variety of drug products including formulations of docetaxel and carboplatin. Celsion licensed the exclusive worldwide rights to the LTSL technology from Duke University.
Products using LTSL: ThermoDox
ThermoDox uses our LTSL technology to encapsulate doxorubicin, a proven and commonly used cancer drug.
ThermoDox is currently being evaluated in a phase 3 study for treatment of primary liver cancer.